Related Experiment Video
Updated: Jul 10, 2026

An Invasive Method for the Activation of the Mouse Dentate Gyrus by High-frequency Stimulation
Published on: June 2, 2018
Clinical application of CNS-acting agents in FSD
1NY Weill Medical College of Cornell University, New York, NY, USA. perelman@earthlink.net
Introduction:
Human sexual response involves a complex sequencing of interrelated mind/body processes. Few treatment options exist that address the complex multilayered etiological determinants of female sexual dysfunction (FSD).
Aim:
Review and evaluate the clinical application of centrally acting agents for the treatment of FSD, with particular emphasis on recently released data on bremelanotide.
Methods:
Review of literature on the treatment of FSD.
Results:
Approaches to FSD treatment have ranged from psychological counseling through a variety of medical interventions along the physiological pathways of sexual function and dysfunction. Despite a great deal of research, especially into hormonal and vasoactive substances, few therapeutics have broad consistent applicability and have withstood scientific scrutiny. Recent clinical trials have investigated the potential role of agents which act on the central nervous system for the treatment of FSD.
Conclusions:
While the recent data supporting the therapeutic use of centrally acting agents as a monotherapy for FSD are cautiously encouraging, there would seem to be tremendous promise for these centrally acting compounds to be integrated with treatment approaches that utilize other pathways in a multilayered, individualized approach to care.
More Related Videos
08:37Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation
Published on: December 22, 2020
11:51Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models
Published on: August 16, 2010
Related Concept Videos
Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Parkinson's Disease: Overview